In a study using preoperative IL-2, 86 colorectal cancer (CRC) patients with stage II/III disease were randomized to receive low dose IL-2 twice a day for 3 consecutive days before surgery or no treatment. The gene discussed is IL2; the disease is colorectal cancer.